A bold move toward the future of healthcare. Zentiva has officially entered the field of biologic medicines with the European launch of its very first biosimilar—a significant milestone that signals both innovation and ambition. But here's where it gets interesting: this isn’t just another product launch; it’s a statement about how the company plans to redefine accessibility in modern medicine across Europe.
Zentiva, long known as a trusted European producer of affordable, high-quality medicines, announced the pan-European approval and rollout of a monoclonal antibody biosimilar following the European Medicines Agency’s (EMA) authorization. This moment marks the company’s formal arrival in the biosimilar arena, a space increasingly seen as the future of sustainable healthcare.
“This is a defining day for Zentiva,” said Steffen Saltofte, CEO of the company. “By stepping into biologics, we’re building upon our promise to make cutting-edge therapies both affordable and accessible for patients throughout Europe.” According to Saltofte, biosimilars—highly similar versions of existing biological drugs—represent a natural evolution of Zentiva’s long-term mission to balance quality with affordability. Yet some industry observers question whether greater competition in this space could disrupt current pricing models. What do you think? Will biosimilars truly deliver on their promise of lower costs without compromising innovation?
The newly launched medicine is a monoclonal antibody designed to treat bone-related conditions, marking Zentiva’s debut in a complex yet fast-growing therapeutic area. The product has received authorization under the EMA’s centralized procedure and will gradually reach European markets beginning in December. And this is the part most people miss: the move doesn’t just expand Zentiva’s portfolio—it positions the company for steady, sustainable growth in one of the pharmaceutical industry’s most rapidly developing sectors.
Zentiva’s expansion into biosimilars ties into a broader corporate strategy to diversify beyond traditional generic medicines. As biologics continue to claim a larger portion of healthcare budgets in Europe, biosimilars are becoming essential to maintain system sustainability and to ensure patients can continue accessing breakthrough therapies without overwhelming healthcare costs.
About Zentiva
Zentiva is dedicated to supporting the health and wellbeing of people across generations. The company develops, manufactures, and distributes affordable, high-quality treatments to more than 100 million patients in over 30 countries throughout Europe and beyond. With four proprietary manufacturing facilities and an extensive network of external partners, Zentiva ensures a stable and reliable supply chain. Its workforce of over 5,000 employees—each driven by a shared commitment to patient care—represents a key strength behind the company’s success. Privately owned and focused on sustainable expansion, Zentiva continues to chart an ambitious growth trajectory. Learn more at www.zentiva.com.
Question for the readers: Do you believe biosimilars will reshape healthcare affordability in Europe—or could they spark new ethical and economic debates within the pharmaceutical world? Join the conversation below and share your thoughts.
